Strata Skin Sciences Inc's ROA from the fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Strata Skin Sciences Inc's ROA in the fourth quarter of 2025?
Strata Skin Sciences Inc recorded a cumulative net loss of $-6 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on assets (ROA) of -17.16%.

However, within the Healthcare sector 363 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Dec 31 2025 quarter, so far to 3874, from total ROA ranking in the third quarter of 2025 at 3897.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Total Assets Change	66.57 %	-22.6 %	-23.91 %	-15.79 %	-16.87 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-6	-12	-13	-10	-11
Return On Assets (TTM)	-17.16 %	-37.86 %	-36.86 %	-27.98 %	-29.3 %
SSKN's Total Ranking	# 3874	# 3897	# 3806	# 4444	# 3782
Total Assets (TTM) in million	58	30	29	33	35
Seq. Total Assets Change	90.87 %	3.35 %	-10.72 %	-5.43 %	-11.31 %
Seq. Net Income Change	-	-	-	-	-

SSKN's 5 Years Annual ROA >> Back to SSKN Management Effectiveness >> Compare SSKN ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 113
Sector	# 364
Overall	# 3524

Return On Assets Statistics
High	Average	Low
4.51 %	-39.49 %	-153.95 %
(Sep 30 2021)		(Mar 31 2014)

Financial Statements
Strata Skin Sciences Inc's Assets	$ 58 million	SSKN's Balance sheet
Strata Skin Sciences Inc's Income	$ 0 million	Quarterly SSKN's Income Statement
SSKN's Income by Division		See SSKN's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	60.91 %	-13.94 %	-19.62 %	12.19 %	-0.4 %
Total Assets in million	58	36	42	52	47
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-6	-10	-11	-6	-3
Annual Return On Assets	-10.76 %	-27.9 %	-25.78 %	-10.62 %	-5.81 %

SSKN's 5 Years Annual ROA >> Back to SSKN Management Effectiveness >> Compare SSKN ROA to its Competitors

More Return On Assets Ratios
SSKN's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SSKN's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SSKN's Competitors
Subscribers only: Roa for Strata Skin Sciences Inc's Suppliers
Subscribers only: Return On Assets for SSKN's Customers

You may also want to know
SSKN's Roi	SSKN's Inventory Turnover Ratio	SSKN's Growth Rates	SSKN's Dividend Comparisons
	SSKN's Profitability Ratios	SSKN's Asset Turnover Ratio	SSKN's Dividend Growth
SSKN's Roe	SSKN's Valuation Ratios	SSKN's Financial Strength Ratios	SSKN's Dividend Payout Ratio

Companies with similar Return On Assets at Dec 31 2025, within Healthcare Sector

ROA

Date modified: 2026-08-29T07:54:02+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.